骨化三醇与胆钙化醇对CKD血管功能的影响:随机双盲试验
该随机双盲试验纳入128例eGFR 15-44 ml/min/1.73 m²且25羟维生素D<30 ng/ml的CKD患者,比较口服胆钙化醇2000 IU/日与骨化三醇0.5 μg/日治疗6个月对血管内皮功能的影响。结果显示两组血流介导的血管扩张均无显著改善,骨化三醇组甲状旁腺激素下降更显著,胆钙化醇组25羟维生素D升高更显著。
要点
- 骨化三醇或胆钙化醇治疗6个月均未改善CKD患者血管内皮功能。
- 骨化三醇降低甲状旁腺激素优于胆钙化醇,胆钙化醇升高25羟维生素D更显著。
- 两种治疗均未改善炎症指标。
核心结论
- 在eGFR 15-44 ml/min/1.73 m²的CKD患者中,骨化三醇或胆钙化醇治疗6个月未改善血管内皮功能或炎症。
研究设计与样本
- 前瞻性、双盲、随机试验,纳入128例成人CKD患者,eGFR 15-44 ml/min/1.73 m²且血清25羟维生素D<30 ng/ml,随机分入口服胆钙化醇2000 IU/日或骨化三醇0.5 μg/日组,治疗6个月。
主要发现
- 6个月后两组血流介导的血管扩张均无显著改善:骨化三醇组基线4.8±3.1%至研究结束5.1±3.6%;胆钙化醇组基线5.2±5.2%至研究结束4.7±3.6%。
- 25羟维生素D在胆钙化醇组较骨化三醇组显著升高(11.0±9.5 ng/ml vs -0.8±4.8 ng/ml,P<0.001)。
- 甲状旁腺激素在骨化三醇组较胆钙化醇组显著下降(中位数[四分位距]:-22.1[-48.7-3.5] pg/ml vs -0.3[-22.6-16.9] pg/ml,P=0.004)。
临床怎么用
- 对于eGFR 15-44 ml/min/1.73 m²且25羟维生素D<30 ng/ml的CKD患者,不应期望通过骨化三醇或胆钙化醇改善血管内皮功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: High circulating vitamin D levels are associated with lower cardiovascular mortality in CKD, possibly by modifying endothelial function. We examined the effect of calcitriol versus cholecalciferol supplementation on vascular endothelial function in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a prospective, double-blind, randomized trial of 128 adult patients with eGFR=15-44 ml/min per 1.73 m2and serum 25-hydroxyvitamin D level <30 ng/ml at the University of Colorado. Participants were randomly assigned to oral cholecalciferol (2000 IU daily) or calcitriol (0.5 μg) daily for 6 months. The primary end point was change in brachial artery flow-mediated dilation. Secondary end points included changes in circulating markers of mineral metabolism and circulating and cellular markers of inflammation. RESULTS: One hundred and fifteen patients completed the study. The mean (SD) age and eGFR of participants were 58±12 years old and 33.0±10.2 ml/min per 1.73 m2, respectively. There were no significant differences between groups at baseline. After 6 months, neither calcitriol nor cholecalciferol treatment resulted in a significant improvement in flow-mediated dilation (mean±SD percentage flow-mediated dilation; calcitriol: baseline 4.8±3.1%, end of study 5.1±3.6%; cholecalciferol: baseline 5.2±5.2%, end of study 4.7±3.6%); 25-hydroxyvitamin D levels increased significantly in the cholecalciferol group compared with the calcitriol group (cholecalciferol: 11.0±9.5 ng/ml; calcitriol: -0.8±4.8 ng/ml; P<0.001). Parathyroid hormone levels decreased significantly in the calcitriol group compared with the cholecalciferol group (median [interquartile range]; calcitriol: -22.1 [-48.7-3.5] pg/ml; cholecalciferol: -0.3 [-22.6-16.9] pg/ml; P=0.004). CONCLUSIONS: Six months of therapy with calcitriol or cholecalciferol did not improve vascular endothelial function or improve inflammation in patients with CKD.
引用
- Kendrick J, Andrews E, You Z, et al. Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial. Clin J Am Soc Nephrol. 2017. PMID: 28784657. doi:10.2215/CJN.01870217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。